Tralokinumab — Membership Pricing

Other medications in Dermatology

• Tretinoin
• Triamcinolone
• Triamcinolone Topical
• Urea Topical
• Acyclovir Topical
• Adapalene
• Anthralin
• Apremilast

About Tralokinumab

Tralokinumab (brand name Adbry) offers a targeted treatment option for adults and adolescents grappling with moderate-to-severe atopic dermatitis. This innovative biologic medication helps improve skin and reduce itching when other treatments fall short. TheDrugClub is dedicated to helping members like you access important medications like tralokinumab, navigating costs to make treatment more affordable.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Tralokinumab is approved for (FDA label)

ADBRY is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and pediatric patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. ADBRY can be used with or without topical corticosteroids. ADBRY is an interleukin-13 antagonist indicated for the treatment of moderate-to-severe atopic dermatitis in adults and pediatric patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. ADBRY can be used with or without topical corticosteroids. ( 1 )

Source: Read the full FDA label on DailyMed. Label effective date: December 17, 2025.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Tralokinumab (FDA label)

ADBRY is a clear to opalescent, colorless to pale yellow solution available as: Injection: 150 mg/mL solution in a single-dose prefilled syringe with needle guard Injection: 300 mg/2 mL solution in a single-dose autoinjector Injection: 150 mg/mL solution in a single-dose prefilled syringe with needle guard. ( 3 ) 300 mg/2 mL solution in a single-dose autoinjector ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: d8020b69-3001-44e2-9b5d-5f93d9aaf6e1. SPL document ID: 8abedac8-f75e-42a0-8591-10fabcf41fb5. Label effective date: December 17, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Tralokinumab (FDA label)

The following adverse reactions are discussed in greater detail elsewhere in the labeling: Hypersensitivity [see Warnings and Precautions (5.1) ] Conjunctivitis and Keratitis [see Warnings and Precautions (5.2) ] Most common adverse reactions (incidence ≥ 1%) are upper respiratory tract infections, conjunctivitis, injection site reactions, and eosinophilia. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact LEO Pharma Inc. at 1-877-494-4536 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: d8020b69-3001-44e2-9b5d-5f93d9aaf6e1. SPL document ID: 8abedac8-f75e-42a0-8591-10fabcf41fb5. Label effective date: December 17, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Tralokinumab (FDA label)

ADBRY is contraindicated in patients who have known hypersensitivity to tralokinumab-ldrm or any excipients in ADBRY [see Warnings and Precautions (5.1) ] . Known hypersensitivity to tralokinumab-ldrm or any excipients in ADBRY. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: d8020b69-3001-44e2-9b5d-5f93d9aaf6e1. SPL document ID: 8abedac8-f75e-42a0-8591-10fabcf41fb5. Label effective date: December 17, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Tralokinumab (FDA label)

Hypersensitivity: Hypersensitivity reactions, including anaphylaxis, and angioedema have occurred after administration of ADBRY. Discontinue ADBRY in the event of a hypersensitivity reaction. ( 5.1 ) Conjunctivitis and Keratitis: Patients should report new onset or worsening eye symptoms to their healthcare provider. ( 5.2 ) Parasitic (Helminth) Infections: Treat patients with pre-existing helminth infections before initiating treatment with ADBRY. If patients become infected while receiving ADBRY and do not respond to anti-helminth treatment, discontinue treatment with ADBRY until the infection resolves. ( 5.3 ) Risk of Infection with Live Vaccines: Avoid use of live vaccines. ( 5.4 ) 5.1 Hypersensitivity Hypersensitivity reactions including anaphylaxis and angioedema have been reported with use of ADBRY. If a serious hypersensitivity reaction occurs, discontinue ADBRY immediately and initiate appropriate therapy. 5.2 Conjunctivitis and Keratitis Conjunctivitis and keratitis occurred more frequently in atopic dermatitis subjects who received ADBRY. Conjunctivitis was the most frequently reported eye disorder.

Source: FDA prescribing information (DailyMed). Set ID: d8020b69-3001-44e2-9b5d-5f93d9aaf6e1. SPL document ID: 8abedac8-f75e-42a0-8591-10fabcf41fb5. Label effective date: December 17, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.